1

1 Systemic hypoxemia catalyzes cerebral oxidative-nitrosative stress during extreme apnea in 2 humans: implications for cerebral bioenergetic function

3 Damian M. Bailey^{1*}, Anthony R. Bain^{2*}, Ryan L. Hoiland^{3,4*}, Otto F. Barak^{5,6}, Ivan Drvis⁷,
4 Benjamin S. Stacey¹, Angelo Iannetelli¹, Gareth W. Davison⁸, Rasmus H. Dahl⁹, Ronan M.G.
5 Berg^{1,10}, David B. MacLeod¹¹, Zeljko Dujic^{5*} and Philip N. Ainslie^{1,12*}

6

7 ¹Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Glamorgan, UK; ²Faculty of Human Kinetics, University of Windsor, Windsor, 8 ON, Canada; ³Department of Anaesthesiology, Pharmacology and Therapeutics, Vancouver 9 10 General Hospital, West 12th Avenue, University of British Columbia, Vancouver, BC, Canada; ⁴Department of Cellular and Physiological Sciences, Faculty of Medicine, University of British 11 Columbia, 2350 Health Sciences Mall, Vancouver, BC, Canada; ⁵School of Medicine, University 12 of Split, Split, Croatia; ⁶Faculty of Medicine, University of Novi Sad, Serbia; ⁷School of 13 Kinesiology, University of Zagreb, Zagreb, Croatia; ⁸Sport and Exercise Science Research 14 Institute, Ulster University Belfast, UK; ⁹Department of Radiology, University Hospital 15 Rigshospitalet, Copenhagen, Denmark; ¹⁰Department of Biomedical Sciences, University of 16 Copenhagen, Denmark; ¹¹Department of Anesthesiology, Duke University Medical Center, 17 Durham, NC, USA and ¹²Center for Heart Lung and Vascular Health, University of British 18 19 Columbia, Kelowna, British Columbia, Canada

20

21 Running title: Redox-regulation of neurovascular complex function

- 22 Keywords: oxygen, carbon dioxide, free radicals, nitric oxide, cerebral bioenergetic function
- 23

24 *contributed equally

25

26 Corresponding author

- 27 Professor Damian Miles Bailey PhD FRSC FACSM FPVRI FTPS
- 28 Royal Society Wolfson Research Fellow
- 29 Director of the Neurovascular Research Laboratory
- 30 Alfred Russel Wallace Building
- **31** Faculty of Life Sciences and Education
- 32 University of South Wales
- **33** UK CF37 4AT
- 34
- **35** Telephone number: +44-1443-482296
- **36** Fax number: +44-1443-482285
- **37** *e*mail: damian.bailey@southwales.ac.uk
- **38** Webpage: http://staff.southwales.ac.uk/users/2240-dbailey1
- **39** Twitter: @USW Oxygen and @DamianMBaileyEP
- 40 Orcid: https://orcid.org/0000-0003-0498-7095

2

41 ABSTRACT

BACKGROUND: Voluntary asphyxia induced by apnea in competitive breath hold (BH) divers
affords a unique opportunity to examine integrated mechanisms underlying the preservation
of cerebral bioenergetic function. This study examined to what extent physiological extremes
of oxygen (O₂) demand and carbon dioxide (CO₂) production impact redox homeostasis and
corresponding red blood cell (RBC)-mediated cerebral vasodilation.

47 **METHODS:** Ten ultra-elite appreists (6 men, 4 women) aged 33 ± 9 (mean \pm SD) years old 48 performed two maximal dry apneas preceded by, [1] normoxic normoventilation resulting in 49 severe hypoxemic hypercapnia apnea (HHA) and [2] hyperoxic hyperventilation designed to 50 prevent hypoxemia resulting in isolated hypercapnic apnea (IHA). Transcerebral exchange 51 kinetics of ascorbate radicals (A, electron paramagnetic resonance spectroscopy), lipid 52 hydroperoxides (LOOH, spectrophotometry) and nitric oxide metabolites (NO, tri-iodide 53 reductive chemiluminescence) were calculated as the product of global cerebral blood flow 54 (gCBF, duplex ultrasound) and radial arterial (a) to internal jugular venous (v) concentration 55 gradients determined at eupnea and after apnea.

56 **RESULTS:** Appead uration increased from 306 ± 62 s during HHA to 959 ± 201 s during IHA (P 57 = <0.001), resulting in individual nadirs of 29 mmHg and 40 % for PaO_2 and SaO_2 respectively 58 in HHA and $PaCO_2$ peak of 68 mmHg in IHA. Apnea resulted in a more pronounced elevation 59 in the net cerebral output (v>a) of A^{-} and LOOH in HHA (P = <0.05 vs. IHA). This coincided 60 with a lower apnea-induced increase in gCBF (P = <0.001 vs. IHA) and related suppression in 61 plasma nitrite (NO₂) uptake (a>v) (P = < 0.05 vs. IHA), implying reduced consumption and 62 delivery of NO consistent with elevated cerebral oxidative-nitrosative stress (OXNOS). While apnea-induced gradients consistently reflected plasma NO₂ consumption (a>v) and RBC iron 63

- 64 nitrosylhemoglobin formation (v>a), we failed to observe equidirectional gradients consistent
- 65 with S-nitrosohemoglobin consumption and plasma S-nitrosothiol delivery.
- 66 CONCLUSIONS: These findings highlight a key catalytic role for hypoxemia in cerebral OXNOS
- 67 with NO_2^{-1} reduction the more likely mechanism underlying endocrine NO vasoregulation with
- 68 the capacity to transduce physiological O₂-CO₂ gradients into graded vasodilation.

4

69 INTRODUCTION

The neurovascular complex (NVC) is a recent concept that highlights the functional interaction between the multi-hetero-cellular structure comprizing the neurovascular unit (NVU) and the systemic vasculature¹. Precisely how the NVC integrates, coordinates and processes molecular signals that collectively maintain cerebral blood flow (CBF) and structural integrity of the blood-brain barrier (BBB) remains to be fully understood, although emergent evidence suggests a key role for redox-regulation².

In support, a neuroprotective hormetic role has emerged for the physiological formation of free radicals and associated reactive oxygen/nitrogen species (ROS/RNS) that enable the sensing and subsequent clearance/delivery of the respiratory gases carbon dioxide (CO₂) and oxygen (O₂) to which the human brain has evolved exquisite sensitivity. In contrast, when excessive and sustained, free radical formation can result in structural destabilization and vascular impairment of the NVU subsequent to oxidative inactivation of vascular nitric oxide (NO), collectively termed oxidative-nitrosative stress (OXNOS)^{3, 4}.

However, to what extent O₂ and CO₂ tensions independently modulate NVC function including the potentially differential impact on the redox-regulation of nitrite (NO₂⁻) and *S*nitrosohemoglobin (SNO-Hb) bioactivity, the principal competing mechanisms underlying endocrine NO vasoregulation⁵, remains to be established. Prolonged apnea performed by ultra-elite breath-hold (BH) divers, given its ability to evoke profound hypoxemic-hypercapnia and compensatory adaptations that preserve bioenergetic homeostasis, affords a unique opportunity to address these knowledge gaps.

90 Extending prior work focused exclusively on BBB integrity⁶, this study combined volumetric
 91 assessment of CBF with concurrent sampling of arterio-jugular venous concentration
 92 differences (a-v_D) to calculate cerebral exchange kinetics of intravascular OXNOS biomarkers

93	in world-class apneists over the course of two maximal, static apneas performed in ambient
94	air. The first was performed following (standard) prior normoxic normoventilation resulting in
95	severe hypoxemia-hypercapnia apnea (HHA) whereas the second followed prior hyperoxic
96	hyperventilation, designed to prevent hypoxemia resulting in isolated hypercapnic apnea
97	(IHA). By manipulating arterial O_2 independent of CO_2 tension, we sought to address the
98	following hypotheses (Figure 1A). First, that cerebral output [venous (v) > arterial (a)] of free
99	radicals and suppression of NO metabolite consumption and CBF would be more pronounced
100	in the normoxic (HHA) compared to hyperoxic (IHA) apnea, implicating hypoxemia as the
101	dominant OXNOS catalyst. Second that the apnea-induced elevation in CBF would be
102	proportional to a net loss (a > v) of NO_2^{-} and SNO-Hb taken to reflect metabolite consumption
103	and delivery of NO.

6

104 METHODS

105 Ethics

106 Experimental procedures were approved by the University of Split, Ethics Committee (#H14-

- 107 00922). All procedures were carried out in accordance with the most (7th) recent amendment
- 108 of the Declaration of Helsinki of the World Medical Association⁷ (with the exception that it
- 109 was not registered in a publicly accessible database prior to recruitment) with verbal and
- 110 written informed consent obtained from all participants.
- 111

112 Participants

113 Ten physically active, elite apneists (6 men, 4 women) aged 33 (mean) \pm 9 (SD) years old with a body mass index of 23 \pm 2 kg/m² and forced vital capacity of 6.40 \pm 1.48 L volunteered from 114 115 the Croatian National Apnea Team. At the time of these experiments, six had placed within 116 the world's top 10 within the last 5 years. One female set a new official world record in 117 dynamic apnea while another male set the world record for apnea following prior hyperoxic 118 hyperventilation (24 min 33 s). A medical examination confirmed that all participants were 119 free of cardiovascular, pulmonary and cerebrovascular disease and were not taking any 120 nutritional supplements including over-the-counter antioxidant or anti-inflammatory 121 medications. They were advised to refrain from physical activity, caffeine and alcohol for 24 122 h prior to formal experimentation and maintain their normal dietary behavior. Participants 123 attended the laboratory following a 12 h overnight fast.

124

125 Design

Parts of this study including blood gas and select aspects of cerebral hemodynamic function(Supplementary material Tables 1-2) have previously been published as part of separate

7

128 investigations focused on the link between hypercapnia and cerebral oxidative metabolism⁸ and hyper-perfusion-mediated structural destabilization of the NVU⁶. Thus, although the 129 130 present study adopted an identical experimental design, it constitutes an entirely separate 131 investigation complemented by *de novo* experimental measures and *a priori* hypotheses 132 focused exclusively on altered redox homeostasis. Participants were required to perform two 133 maximal apneas preceded by, [1] normoxic normoventilation resulting in severe hypoxemic 134 hypercapnia apnea (HHA) and [2] hyperoxic hyperventilation designed to prevent hypoxemia 135 resulting in isolated hypercapnic apnea (IHA). The order of trials was non-randomized given 136 the long-lasting carryover effects of hyperoxia and fatigue associated with a more prolonged apnea⁸. Data were collected at baseline and timed to coincide with the point of apnea 137 138 termination (Figure 1B).

139

140 Procedures

141 All apneas were completed on a single day with the Croatian national apnea coach present to 142 motivate divers and ensure maximal efforts. Each apnea was preceded by 30 min of supine 143 rest followed by two standardized preparatory (practice) apneas designed to maximize the 144 experimental apneas (see below). The first preparatory apnea was performed at functional 145 residual capacity (FRC) until seven involuntary breathing movements (IBMs) were attained. 146 Two minutes later, the second preparatory apnea was performed at total lung capacity (TLC) 147 lasting for ten IBMs. Participants then rested quietly for 6 min prior to two 'maximal' apneas 148 that were each performed at TLC:

149

150

8

- **152** *Trial 1: Prior normoxic normoventilation- hypoxemic hypercapnia apnea (HHA)*
- 153 Participants performed a maximal apnea in room air (normoxia).

154

- 155 Trial 2: Prior hyperoxic hyperventilation- isolated hypercapnic apnea (IHA)
- **156** Participants performed a maximal apnea preceded by 15 min of hyperventilation of 100% O₂
- while receiving auditory feedback from the coach to achieve an end tidal PCO_2 (PET_{CO2}) of ~20
- 158 mmHg.
- 159
- 160 Blood sampling

161 Catheterization

162 Participants were placed slightly head down on a hospital bed, and two catheters were 163 inserted retrograde using the Seldinger technique under local anesthesia (1 % lidocaine) via 164 ultrasound guidance. A 20-guage arterial catheter (Arrow, Markham, ON, Canada) was placed in the right radial artery (a) and attached to an in-line waste-less sampling setup (Edwards 165 166 Lifesciences VAMP, CA, USA) connected to a pressure transducer that was placed at the 167 height of the right atrium (TruWave transducer). A central venous catheter (Edwards 168 PediaSat Oximetry Catheter, CA, USA) was placed in the right internal jugular vein (v) and 169 advanced towards the jugular bulb located at the mastoid process, approximately at the C1-170 C2 interspace (Figure 1). Facial vein contamination was ruled out by ensuring that all jugular 171 venous oxyhemoglobin saturation (SO₂) values were < 75% at rest. Participants rested for at 172 least 30 min following catheter placement prior to the collection of baseline samples. 173

- 1/5
- 174

9

176 *Collection and storage*

177 Blood samples were drawn without stasis simultaneously from the RA and JV directly into 178 Vacutainers (Becton, Dickinson and Company, Oxford, UK) before centrifugation at 600g (4°C) 179 for 10 min. With the exception of blood for determination of blood gas variables, plasma and 180 red blood cell (RBC) samples were decanted into cryogenic vials (Nalgene Labware, Thermo 181 Fisher Scientific Inc, Waltham, MA) and immediately snap-frozen in liquid nitrogen (N_2) 182 before transport under nitrogen gas (Cryopak, Taylor-Wharton, Theodore, AL) from Croatia to the United Kingdom. Samples were left to defrost at 37°C in the dark for 5 minutes prior to 183 184 batch analysis.

185

186 Measurements

187 Blood gases

188 Whole blood was collected into heparinized syringes, maintained anerobically at room 189 temperature and immediately analyzed for hemoglobin (Hb), hematocrit (Hct), partial 190 pressures of oxygen, carbon dioxide (PO₂/PCO₂), SO₂, pH and glucose (Glu) using a 191 commercially available cassette-based analyzer (ABL-90 FLEX, Radiometer, Copenhagen, 192 Denmark). Hydrogen ion (H⁺) concentration was calculated as [H⁺] = 10^{-pH} . The intra- and 193 inter-assay CVs for all metabolites were both <5%⁹.

194

195 Antioxidants

196 Plasma was stabilized and deproteinated using 10% metaphosphoric acid (Sigma Chemical, 197 Dorset, UK). Ascorbic acid was assayed by fluorimetry based on the condensation of 198 dehydroascorbic acid with 1,2-phenylenediamine¹⁰. Concentrations of the lipid soluble 199 antioxidants (LSA) encompassing α/γ -tocopherol, α/β -carotene, retinol and lycopene were

10

200 determined using high-performance liquid chromatography (HPLC)^{11, 12}. The intra- and inter-

201 assay CVs for both metabolites were both $<5\%^9$.

202 Free radicals

203 Ascorbate free radical (A⁻): We employed electron paramagnetic resonance (EPR) 204 spectrosopic detection of A⁻⁻ as a direct measure of global systemic free radical formation⁹. 205 Plasma (1 mL) was injected directly into a high-sensitivity multiple-bore sample cell (AquaX, 206 Bruker Daltonics Inc., Billerica, MA, USA) housed within a TM_{110} cavity of an EPR 207 spectrometer operating at X-band frequency (9.87 GHz). Samples were recorded by 208 cumulative signal averaging of 10 scans using the following instrument parameters: 209 resolution, 1024 points: microwave power, 20 mW; modulation amplitude, 0.65 G; receiver gain, 2×10^6 ; time constant, 40.96 ms; sweep rate, 0.14 G/s; sweep width, 6 G; centre field, 210 211 3486 G. All spectra were filtered identically (moving average, 15 conversion points) using 212 WINEPR software (Version 2.11, Bruker, Karlsruhe, Germany) and the double integral of each 213 doublet quantified using Origin 8 software (OriginLab Corps, MA, USA). The intra- and inter-214 assay CVs were both $<5\%^9$.

215

Lipid hydroperoxides (LOOH): LOOH were determined spectrophotometrically via the ferric
 oxidation of xylenol orange (FOX) version II method, with modification⁹. Intra- and inter-assay
 CVs were <2 % and <4 % respectively⁹.

219

220 Nitric oxide (NO) metabolites

Ozone-based chemiluminescence (Sievers NOA 280i, Analytix Ltd, Durham, UK) was used to
detect NO liberated from plasma and RBC samples via chemical reagent cleavage facilitating
detection of plasma and red blood cell (RBC) NO₂, S-nitrosothiols (RSNO), S-

11

224	nitrosohemoglobin (SNO-Hb) and iron nitrosylhemoglobin (HbNO) according to established
225	methods ¹³⁻¹⁵ . Total NO bioactivity was calculated as the cumulative concentration of plasma
226	and RBC metabolites. Signal output was plotted against time using Origin 8 software
227	(OriginLab Corps, Massachusetts, USA) and smoothed using a 150-point averaging algorithm.
228	The Peak Analysis package was used to calculate the area under the curve and subsequently
229	converted to a concentration using standard curves of sodium NO_2^{-} . Intra- and inter-assay CVs
230	for all metabolites were both $<10\%^{13}$.

231

232 Cardiopulmonary function

233 All cardiopulmonary measurements were averaged over 15 s immediately prior to blood 234 sampling. A lead II electrocardiogram (Dual BioAmp; ADInstruments, Oxford, UK) was used to 235 measure heart rate (HR). Intra-arterial ABP was recorded directly via a pressure transducer 236 placed at the level of the heart for determination of mean arterial pressure (MAP). Internal 237 jugular venous pressure (IJVP) was measured with the transducer connected to the jugular 238 catheter. End-tidal partial pressures of oxygen and carbon dioxide (PET $_{O2/CO2}$) were measured 239 via capnography (ML 206, ADInstruments Ltd, Oxford, UK). Finger photoplethysmography 240 (Finometer PRO, Finapres Medical Systems, Amsterdam, The Netherlands) was used to measure beat-by-beat stroke volume (SV) and cardiac output (\dot{Q}) using the Modelflow 241 algorithm¹⁶ that incorporates participant sex, age, stature and mass (BeatScope 1.0 software; 242 243 TNO; TPD Biomedical Instrumentation, Amsterdam, The Netherlands).

244

245 Cerebrovascular function

246 *Intracranial:* Blood velocity in the middle cerebral artery (MCAv, insonated through the left
247 temporal window and posterior cerebral artery (PCAv, insonated at the P1 segment through

12

the right temporal window) were measured using standardized procedures with a 2 MHz
pulsed transcranial Doppler ultrasound (TCD; Spencer Technologies, Seattle, WA, USA).
Bilateral TCD probes were secured using a specialized commercial headband (Mark600,
Spencer Technologies, Seattle, WA, USA) using standardized search techniques.

252

253 Extracranial: Continuous diameter, velocity and blood flow recordings in the right internal 254 carotid and left vertebral arteries $(\dot{Q}_{ICA}/\dot{Q}_{VA})$ were obtained using a 10 MHz, multifrequency, 255 linear array vascular ultrasound (Terason 3200, Teratech, Burlington, MA). Arterial diameter 256 was measured via B-mode imaging, whereas peak blood velocity was simultaneously 257 measured with pulse-wave mode. The ICA was insonated ≥1.5 cm from the carotid 258 bifurcation, with no evidence of turbulent or retrograde flow present during recording. The 259 VA was insonated at the C4–C5 or C5–C6 vertebral segment and standardized within 260 participants for the HHA and IHA trials. The steering angle was fixed to 60° and the sample 261 volume was placed in the center of the vessel and adjusted to cover the entire vascular 262 lumen. All images were recorded as video files at 30 Hz and stored for offline analysis using customized edge detection software designed to mitigate observer bias¹⁷. Simultaneous 263 264 measures of arterial diameter and velocity over >12 consecutive cardiac cycles were used to 265 calculate flow. Between-day CVs for \dot{Q}_{ICA} and \dot{Q}_{VA} are 5 % and 11 %, respectively¹⁸.

266

267 Data integration

All cardiopulmonary measurements were sampled at 1 kHz and integrated into PowerLab[®]
and LabChart[®] software (ADInstruments, Bella Vista, NSW, Australia) for online monitoring
and saved for offline analysis.

13

```
272
```

273 Calculations

- 274 Cerebral bioenergetics
- 275 *Perfusion:* Volumetric blood flow was calculated offline as:

276 $\dot{Q}_{ICA} \text{ or } \dot{Q}_{VA} \text{ (mL/min)} = \frac{\text{peak envelope blood velocity}}{2} \times [\pi (0.5 \times \text{diameter})^2] \times 60$

277 \dot{Q}_{ICA} or \dot{Q}_{VA} were averaged for a 1 min eupnea baseline and during the last 30 s of apnea.

278

279 During the latter half of each apnea, IBMs and corresponding contraction of the 280 sternocleidomastoid prevented reliable blood velocity traces. To circumvent this, Q_{ICA} and 281 Q_{VA} were estimated (e) from changes in MCAv (for \dot{Q}_{ICA}) and PCAv (for \dot{Q}_{VA}) respectively, as 282 previously described^{19, 20}:

283

284 Apnea eICAv and eVAv = Eupnea ICAv and VAv ×
$$\left(\frac{\text{Apnea MCAv or PCAv}}{\text{Eupnea MCAv or PCAv}}\right)$$

285
$$\dot{Q}_{ICA} \text{ or } \dot{Q}_{VA} \text{ (mL/min)} = eICAv \text{ or } eVAv \times \pi \left(\frac{\text{diameter}}{2}\right)^2$$

286

287 Assuming symmetrical blood flow of contralateral ICA and VA arteries, global cerebral blood

288 flow (gCBF) was calculated as:

289

290 gCBF (mL/min) = $2 \times (\dot{Q}_{ICA} + \dot{Q}_{VA})$

291

292 Cerebral perfusion pressure (CPP) was calculated as MAP-IJVP with the latter serving as a
 293 surrogate for ICP²¹.

14

295 Metabolism: Arterial and jugular venous oxygen content (caO₂ and cvO₂ respectively) were

296 calculated as:

297
$$caO_2 (mL/dL) = Hb (g/dL) \times 1.34 \left(\frac{SaO_2(\%)}{100}\right) + 0.003 \times PaO_2$$

298
$$\text{cvO}_2 (\text{mL/dL}) = \text{Hb} (\text{g/dL}) \times 1.34 \left(\frac{\text{SvO}_2(\%)}{100}\right) + 0.003 \times \text{PvO}_2$$

299

300 where 1.34 is the O_2 binding capacity of Hb and 0.003 is the solubility of O_2 dissolved in

301 blood.

302

303 Global cerebral O₂ and glucose delivery (gCDO₂/gCD_{Glucose}) were calculated as:

304 gCDO₂ (mL/min) =
$$\left(\frac{\text{gCBF}(\text{mL/min})}{100}\right) \times \text{caO}_2 (\text{mL/dL})$$

305

306
$$gCD_{Glu} (mmol/min) = \left(\frac{gCBF (mL/min)}{1000}\right) \times a_{Glucose} (mmol/L)$$

307

308 The cerebral metabolic rate of oxygen (CMRO₂) and glucose (CMR_{Glucose}) were calculated as:

309 CMRO₂ (mL/min) =
$$\left(\frac{\text{gCBF}(\text{mL/min})}{100}\right) \times \text{caO}_2\text{-cvO}_2$$
 (mL/dL)

311
$$CMR_{Glucose} (mmol/min) = \left(\frac{gCBF (mL/min)}{1000}\right) \times a_{Glucose} - v_{Glucose} (mmol/L)$$

312

313 Transcerebral exchange kinetics

316 gCPF (mL/min) = gCBF
$$\left(1 - \frac{\text{Hct}_a}{100}\right)$$

15

317

318 gCRBCF (mL//min) = gCBF
$$\left(\frac{\text{Hct}_a}{100}\right)$$

for corresponding calculation of net transcerebral exchange kinetics of plasma/serum/RBC-

320 borne metabolites according to the Fick principle:

321

322 Exchange (μ mol or nmol/min) = gCBF or gCPF or gCRBCF × ($a - v_D$).

323 By convention, a positive value (a>v) refers to net uptake (loss or consumption) whereas a

negative value (v>a) indicates net output (gain or formation) across the cerebrovascular bed.

325

326 Data analysis

327 Data were analyzed using the Statistics Package for Social Scientists (IBM SPSS Statistics 328 Version 29.0). Distribution normality was confirmed using Shapiro-Wilk W tests (P > 0.05). 329 Data were analyzed using a combination of two (State: Eupnea vs. Apnea × Site: Arterial vs. 330 Venous) and three (*Trial*: HHA vs. IHA × State: Eupnea vs. Apnea × Site: Arterial vs. Venous) 331 factor repeated measures analyzes of variance. Post-hoc Bonferroni-corrected paired 332 samples *t*-tests were employed to locate differences following an interaction. Relationships 333 between selected variables were analyzed using Pearson Product Moment Correlations. 334 Significance was established at P < 0.05 for all two-tailed tests and data presented as mean \pm 335 SD.

16

337 RESULTS

- 338 Apnea
- 339 Apnea duration increased from 306 \pm 62 s (range: 217-409 s) during HHA to 959 \pm 201 s
- **340** (range: 579-1262 s) during IHA (P = <0.001).
- 341

342 Blood gas variables

343 As expected, apnea induced severe systemic and local hypoxemia (\downarrow PO₂, \downarrow SO₂, \downarrow cO₂),

hypercapnia (\uparrow PCO₂) and acidosis (\downarrow pH, \uparrow HCO₃) in NX (Supplemental Table 1). In one participant, nadirs of 29 mmHg and 40 % were recorded for PaO₂ and SaO₂ respectively, corresponding to a (peak) PaCO₂ of 53 mmHg in HHA. Participants were hypocapnic at eupnea in IHA and remained hyperoxemic and comparatively less hypertensive and more hypercapnic/acidotic throughout apnea (Supplemental Table 1). The highest individual value recorded for PaCO₂ during IHA was 68 mmHg corresponding to a pH of 7.227. Baseline levels

of Hb and Hct at eupnea were elevated in IHA (Supplemental Table 1).

351

352 Cardiopulmonary function

Apnea decreased SV and Q in HHA whereas increases were observed in IHA (Table 1). Apnea
was associated with a general increase in MAP, IJVP and CPP that were more pronounced in
HHA (Supplemental Table 1).

356

357 Cerebral bioenergetics

358 Compared to the eupnic control states (normoxic normocapnia), a greater increase in gCBF 359 was observed in IHA (+206 ± 52 %) compared to HHA (+83 ± 22 %, P = <0.001) due to 360 consistently lower \dot{Q}_{ICA} and \dot{Q}_{VA} values at baseline subsequent to (hyperoxic)

17

hyperventilation-induced hypocapnia (Supplemental Table 3). Corresponding increases in
local (VA/ICA) and global cerebral substrate delivery (O₂ and glucose) were also more
pronounced during apnea in IHA (Supplemental Table 3). Apnea generally decreased CMRO₂
whereas CMR_{Glu} remained preserved with no differences between trials (Supplemental Table
3). **Oxidative stress**

368 Apnea increased the a- v_D and corresponding net cerebral uptake of ascorbate, α -tocopherol 369 and total LSA that were more pronounced in HHA (Table 1, Figure 2 A-C). This was 370 accompanied by a reduction in the a- v_D and reciprocal elevation in the net cerebral output of 371 A⁻⁻ and LOOH that were also more marked in HHA for A⁻⁻ (Table 1, Figure 2 D-E).

372

373 Nitrosative stress

374 Figure 3 highlights the dynamic interplay and re-apportionment of NO metabolites across the 375 cerebral circulation observable within the constraints of a single a-v transit. The total NO 376 metabolite pool was generally lower in HHA and during apnea due to a combined reduction in plasma and RBC NO_2^{-} whereas elevations were observed in SNO-Hb and HbNO (Table 2, 377 Figure 3). Corresponding differences translated into net cerebral uptake of plasma NO₂, 378 379 RSNO and RBC NO_2^{-} (Figure 4 A-B, D) that were opposed by net cerebral output of SNO-Hb and HbNO (Figure 4 E-F). Plasma NO₂ uptake and SNO-Hb/HbNO output were more 380 pronounced during apnea, with plasma NO_2^{-} uptake generally lower in HHA (Figure 4 A, E-F). 381 382 The apnea-induced elevation in A^{-} output was associated with a reduction in plasma NO_{2}^{-} 383 uptake in HHA (r = 0.702, P = 0.024) but not IHA (r = 0.509, P = 0.133).

18

384 DISCUSSION

385 Local sampling of blood across the cerebral circulation during maximal apnea in world-class 386 BH divers has provided important insight into the mechanisms underlying the redox-387 regulation of cerebral bioenergetic function during the most severe extremes of O_2 388 demand/ CO_2 production recorded to date in unanesthetized and otherwise healthy humans²². Direct measures of intravascular OXNOS and inclusion of the IHA trial designed to 389 390 prevent hypoxemia and better distinguish between competing vasoactive stimuli, highlights 391 three novel findings. First, the combined elevation in the net cerebral output of A⁻ and LOOH 392 during apnea, collectively taken to reflect increased free radical-mediated lipid peroxidation, 393 was more pronounced in HHA, highlighting a key contribution for hypoxemia. Second, this 394 coincided with a lower apnea-induced elevation in gCBF and related suppression in plasma NO_2^- uptake, implying reduced consumption and delivery of NO consistent with increased 395 OXNOS. Finally, that apnea-induced NO_2^- uptake and HbNO output prevailed in the face of 396 increased SNO-Hb output and (general) RSNO uptake, tentatively suggests NO_2^- reduction as 397 398 the more likely mechanism underlying endocrine NO vasoregulation with the capacity to 399 transduce physiological O_2 -CO₂ gradients into graded vasodilation. Collectively, these findings 400 highlight the dynamic interplay that takes place between free radicals and NO metabolites 401 during a single arteriovenous transit across the cerebral circulation and corresponding 402 implications for cerebral bioenergetic function that may have clinical translational relevance.

403

404 Hypoxemia is a key stimulus for cerebral OXNOS

405 We recently documented molecular evidence for structural destabilization of the NVU that406 was selectively more pronounced during apnea in HHA compared to IHA despite

19

407 comparatively suppressed, albeit concerted vasodilation⁶. While this was originally attributed
408 purely to the 'mechanical' stress imposed by more severe systemic and intracranial
409 hypertension caused by hypoxemia, the present findings suggest a potentially additive role
410 for 'chemical' stress, taking the form of elevated OXNOS, to which the human brain is
411 especially vulnerable.

412 To do this, we employed EPR spectroscopic detection of the distinctive A⁻⁻ 'doublet' as a 413 direct biomarker of global free radical formation with LOOH serving as a distal reactant of lipid peroxidation⁹. That net cerebral uptake (a>v) of ascorbate, α -tocopherol and (total) LSA 414 415 was observed during apnea in both trials, and more pronounced in HHA, was taken to reflect 416 enhanced sacrificial consumption (uptake by brain parenchyma and/or blood-borne reactions 417 during circulatory transit) to constrain chain initiation-propagation reactions. However, this 418 failed to prevent the overall shift in redox imbalance favouring increased free radical-419 mediated lipid peroxidation confirmed by proportional increases in the net cerebral output of 420 A^{-} and LOOH (v>a) that were selectively elevated in HHA. The greater elevation in A^{-} output 421 in HHA exceeded that predicted by prior modelling due to more ascorbate available for oxidation²³ (given increased consumption), highlighting authentic (i.e. *de novo*) free radical 422 423 formation. Our measured A⁻ gradients in HHA (v = 37 % > a) also exceeded those previously recorded during HHA in a separate group of elite apneists²⁴ (v = 4 % > a) and were even more 424 pronounced than those documented during vigorous cycling exercise⁹ (v = 12 % > a) - helping 425 426 place its magnitude into clearer physiological context.

427 While it is conceivable that hypoxemia, hypercapnia and hyperoxemia independently 428 contributed towards global oxidative stress, it was not experimentally possible to fully 429 differentiate between stimuli, only combinations thereof. Hypoxemia and hyperoxemia 430 independently generate mitochondrial superoxide (O₂⁻⁻) and NO⁻, notwithstanding

20

431 contributions from extra-mitochondrial sources including nicotinamide adenine dinucleotide 432 phosphate- and xanthine oxidases, cytochrome P-450 enzymes, lipoxygenases and 433 phagocytes, that can further propagate oxidative stress via secondary formation of hydrogen 434 peroxide (H_2O_2) , peroxynitrite (ONOO⁻) and Haber-Weiss/Fenton catalyzed hydroxyl radicals (OH⁻⁾)^{25, 26}. Furthermore, the addition of (hypercapnic) acidosis, common to both trials yet 435 436 more severe in HX given the extended BH times, would have been expected to further 437 amplify oxidation since molecular CO₂ can react with ONOO⁻ and H_2O_2 to form redox reactive carbonate radicals and peroxymonocarbonate²⁷. However, that cerebral oxidative stress was 438 439 considerably more pronounced in HHA suggests a key catalytic role for hypoxemia that far 440 outweighed the additive effects of hyperoxemia and (more severe) hypercapnia, confirming prior observations in healthy humans albeit exposed to poikilocaphic (hypocaphic) hypoxia⁹, 441 28 442

To what extent this represents a physiologically adaptive (molecular signalling) or pathologically maladaptive (structurally damaging) response remains unclear given the pleiotropic mechanisms underlying redox-regulation of NVU function⁴. That oxidative stress was elevated in the face of reduced gCMRO₂ and gCMR_{Glucose}, attributable in part to hypercapnia⁸, has also been observed in (more) anoxia–hypoxia-tolerant vertebrates and interpreted to reflect an adaptive O₂-conserving strategy to improve neuronal survival²⁹.

However, two observations in the present study tentatively suggest that the overall impact was likely maladaptive. First, that apnea in NX was associated with a lower net uptake of plasma NO_2^- implied reduced consumption of NO, potentially tempering vasodilation (see below). This may reflect oxidative inactivation of NO by O_2^- and/or secondary lipid-derived alkoxyl-alkyl radicals formed subsequent to the reductive decomposition of (elevated) LOOH

21

to form ONOO⁻, collectively taken as evidence for elevated OXNOS ($O_2^{-}/LO^{-}/LC^{-} + NO \xrightarrow{10^9 M/s}$ ONOO⁻)³⁰. Second, that our prior research has shown that apnea induces mild disruption of the BBB and increased neuronal-gliovascular reactivity that were consistently more pronounced in HHA⁶, stands testament to the thermodynamic potential of radicals to cause structural damage to the NVU, which is not unreasonable given its histological vulnerability⁴, ³¹.

460

461 NO metabolites and vasoregulation

462 Our findings highlight that the NO metabolite pool is in a perpetual state of dynamic flux 463 even within the time constraints of a single a-v transit and that metabolite re-apportionment 464 between plasma and RBC compartments is not solely related to changes in O₂ but also involves CO_2 and pH (Figure 3). By measuring corresponding gradients of NO_2^{-} and SNO-Hb, 465 466 the principal metabolites capable of transducing NO bioactivity within the cerebral microcirculation^{32, 33}, we sought to determine if differential changes could further inform the 467 468 mechanism(s) underlying cerebral vasodilation across extremes of PaO₂ and PaCO₂. Both metabolites likely originated from the combined effects of apnea-induced elevations in 469 shear-mediated conduit vessel endothelial³⁴, neuronal³⁵ NO synthase bioactivation and 470 transpulmonary S-nitrosylation³²; however, their respective roles in endocrine NO signalling 471 472 and cerebral bioenergetic function remain widely contested, albeit unified by allostericcoupled Hb deoxygenation and acidic disproportionation 5 . 473

474 The NO_2^- reductase hypothesis favors NO_2^- as the major intravascular NO storage molecule 475 with conversion to NO or dinitrogen trioxide (N₂O₃) catalyzed by deoxyHb-mediated 476 reduction and acidic disproportionation^{13, 33, 36}. In contrast, the SNO-Hb hypothesis contends

22

477 that NO is stabilized, transported, and delivered by intra-molecular NO group transfers 478 between the heme iron and β -93 cysteine, that upon deoxygenation releases an as of yet 479 unidentified moiety that is exported from the RBC involving transnitrosylation of the anion exchanger AE1, as a low molecular weight RSNO to effect vasodilation^{32, 37, 38}. 480 481 The direction and magnitude of gradients observed are generally more consistent with those predicted by the NO₂ reductase (as opposed to the SNO-Hb) hypothesis. In support, systemic 482 (a) plasma $N\bar{O_2}$ fell during apnea and was accompanied by a concomitant increase in net 483 484 uptake implying consumption from artery to vein (a>v), although we cannot discount consistently elevated NO₂ formation on the arterial side due to elevated NOS activity. Plasma 485 NO_2^- consumption was especially marked in HX, coinciding with the most pronounced 486 487 elevation in gCBF and where the total NO metabolite pool was greatest. This was 488 accompanied by NO formation with concomitant output (v>a) of HbNO, albeit suppressed in 489 IHA consistent with the prevailing SO_2 since hyperoxemia persisted at end apnea, culminating 490 in an overall net gain in NO metabolites. These findings were taken to reflect a combination of deoxyHb-mediated reduction of NO_2^{-} in the RBC and acidic disproportionation subsequent 491 492 to marked hypercapnia-induced acidosis. Local formation of NO, potentially compounded by the observed increase in ascorbate consumption³⁹, binds to vicinal deoxyHb yielding HbNO 493 494 (Equations 1 and 2) and, to a lesser extent, the intermediate nitrosating species dinitrogen trioxide that can escape the RBC to effect graded vasodilation³³: 495 NO_2^- + HbFe²⁺(deoxyHb) + H⁺ $\xrightarrow{0.47 \text{ M/s}}$ HbFe³⁺ (metHb) + NO + OH⁻ 496 (Equation

497 1)

498 NO + HbFe²⁺
$$\xrightarrow{0.18 \text{ M/s}}$$
 HbFe²⁺NO (HbNO) (Equation2)

23

499

500 The gradients observed reproduce those previously documented across the exercising 501 human forearm circulation and NO_2^{-} infusion that originally informed the NO_2^{-} reductase 502 hypothesis^{33, 36}. Similar gradients were more recently documented across the cerebral 503 circulation at rest and in response to acute exercise during hypocapnic hypoxia¹³.

504 In contrast, that apnea stimulated SNO-Hb output (v>a) and RSNO uptake (a>v) argues 505 against the SNO-Hb hypothesis, since the gradients observed were diametrically opposed to those originally predicted⁴⁰, yet consistent with the observations of other research 506 laboratories^{41, 42}. We would have expected an allosterically mediated release from a-v during 507 508 circulatory transit, resulting in a drop in the RBC and corresponding rise in plasma RSNO in 509 the venous circulation, consistent with SNO-Hb consumption (a>v) and RSNO delivery (v>a)510 during local deoxygenation. Yet, the gradients observed consistently reflected SNO-Hb 511 formation (v>a) and RSNO consumption (a>v), that in the former, was further compounded 512 during apnea and unrelated to the increase in gCBF.

513

514 Experimental limitations

515 Several limitations warrant consideration. First, it was not possible to fully disassociate 516 changes in PaO_2 from $PaCO_2$, only combinations thereof, given the inability to 'match' end-517 apnea hypercapnia that was unavoidably more pronounced in HX owing to extended BH 518 times. Second, it was unfortunate that we did not measure plasma 3-nitrotyrosine due to 519 inadequate sample volume: its elevation would have indirectly confirmed increased ONOO⁻ 520 formation subsequent to oxidative inactivation of NO underlying OXNOS, consistent with our prior observations in hypoxia³⁵. Third, the profiling of NO metabolite gradients, while 521 522 informative, fails to unequivocally identify the specific NO species responsible for conserving

523	bioactivity and the mechanism(s) underpinning vasoregulation, including potential
524	contributions from ATP-mediated activation of P_{2Y} receptors. Finally, despite prospective
525	power calculations informed by our prior research ²⁴ , we acknowledge the small sample sizes
526	employed may have limited our ability to detect treatment effects, albeit challenging to
527	perform large-scale invasive studies of this nature. Caveats notwithstanding, mapping the
528	dynamic transvascular interplay of OXINOS biomarkers in this applied model of human
529	asphyxia may prove clinically relevant in that it may help define more sensitive biomarkers of
530	cerebrovascular health and inform interventions designed to optimize tissue oxygenation in
531	the critically ill.

532 REFERENCES

- 533 1. Schaeffer S and Iadecola C. Revisiting the neurovascular unit. *Nat Neurosci*.
 534 2021;24:1198-1209.
- 535 2. Rinaldi C, Donato L, Alibrandi S, Scimone C, D'Angelo R and Sidoti A. Oxidative Stress
- and the Neurovascular Unit. *Life (Basel)*. 2021;11.
- 537 3. Bailey DM. Oxygen, evolution and redox signalling in the human brain; quantum in the
- **538** quotidian. *The Journal of physiology*. 2019;597:15-28.
- 539 4. Cobley JN, Fiorello ML and Bailey DM. 13 reasons why the brain is susceptible to
- 540 oxidative stress. *Redox biology*. 2018;15:490-503.
- 541 5. Gladwin MT and Schechter AN. NO contest: nitrite versus S-nitroso-hemoglobin.
- **542** *Circulation Research*. 2004;94:851-5.
- 543 6. Bailey DM, Bain AR, Hoiland RL, Barak OF, Drvis I, Hirtz C, Lehmann S, Marchi N,
- 544 Janigro D, MacLeod DB, Ainslie PN and Dujic Z. Hypoxemia increases blood-brain barrier
- 545 permeability during extreme apnea in humans. Journal of cerebral blood flow and metabolism
- 546 : official journal of the International Society of Cerebral Blood Flow and Metabolism.
- **547** 2022;42:1120-1135.

548 7. WMA. World Medical Association Declaration of Helsinki: ethical principles for
549 medical research involving human subjects. *Journal of the American Medical Association*.
550 2013;310:2191-4.

Bain AR, Ainslie PN, Barak OF, Hoiland RL, Drvis I, Mijacika T, Bailey DM, Santoro A,
 DeMasi DK, Dujic Z and MacLeod DB. Hypercapnia is essential to reduce the cerebral
 oxidative metabolism during extreme apnea in humans. *Journal of Cerebral Blood Flow and Metabolism*. 2017:271678X16686093.

26

555	9. Bailey DM, Rasmussen P, Evans KA, Bohm AM, Zaar M, Nielsen HB, Brass	ard P,
556	Nordsborg NB, Homann PH, Raven PB, McEneny J, Young IS, McCord JM and Seche	er NH.
557	Hypoxia compounds exercise-induced free radical formation in humans; partit	ioning
558	contributions from the cerebral and femoral circulation. Free Radical Biology & Medicine	2
559	2018;124:104-113.	
560	10. Vuilleumier JP and Keck E. Fluorimetric assay of vitamin C in biological materials	using
561	a centrifugal analyser with fluorescence attachment. Journal of Micronutritional An	alysis.
562	1993;5:25-34.	
563	11. Catignani GL and Bieri JG. Simultaneous determination of retinol and	alpha-
564	tocopherol in serum or plasma by liquid chromatography. Clinical Chemistry. 1983;29	9:708-
565	712.	
566	12. Thurnham DI, Smith E and Flora PS. Concurrent liquid-chromatographic as	say of
567	retinol, <i>a</i> -tocopherol, $m{ heta}$ -carotene, <i>a</i> -carotene, lycopene, and $m{ heta}$ -cryptoxanthin in plasma	, with
568	tocopherol acetate as internal standard. Clinical Chemistry. 1988;34:377-381.	
569	13. Bailey DM, Rasmussen P, Overgaard M, Evans KA, Bohm AM, Seifert T, Brass	ard P,
570	Zaar M, Nielsen HB, Raven PB and Secher NH. Nitrite and S-Nitrosohemoglobin exc	hange
571	across the human cerebral and femoral circulation: relationship to basal and exercise	blood
572	flow responses to hypoxia. Circulation. 2017;135:166-176.	
573	14. Rogers SC, Khalatbari A, Gapper PW, Frenneaux MP and James PE. Detecti	on of
574	human red blood cell-bound nitric oxide. Journal of Biological Chemistry. 2005;280:2	6720-
575	26728.	
576	15. Pinder AG, Rogers SC, Khalatbari A, Ingram TE and James PE. The measurem	ent of

577 nitric oxide and its metabolites in biological samples by ozone-based chemiluminescence.

578 *Methods in molecular biology*. 2009;476:10-27.

27

579 16. Wesseling KH, Jansen JR, Settels JJ and Schreuder JJ. Computation of aortic flow from

pressure in humans using a nonlinear, three-element model. *Journal of applied physiology*.
1993;74:2566-73.

582 17. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB,

583 Beilin LJ, Burke V, Mori TA and Green D. Improved analysis of brachial artery ultrasound using

a novel edge-detection software system. *Journal of applied physiology*. 2001;91:929-37.

585 18. Willie CK, Macleod DB, Shaw AD, Smith KJ, Tzeng YC, Eves ND, Ikeda K, Graham J,

586 Lewis NC, Day TA and Ainslie PN. Regional brain blood flow in man during acute changes in

s87 arterial blood gases. *Journal of Physiology*. 2012;590:3261-75.

588 19. Hoiland RL, Ainslie PN, Bain AR, MacLeod DB, Stembridge M, Drvis I, Madden D, Barak

589 O, MacLeod DM and Dujic Z. Beta1-Blockade increases maximal apnea duration in elite
590 breath-hold divers. *Journal of applied physiology*. 2017;122:899-906.

591 20. Willie CK, Ainslie PN, Drvis I, MacLeod DB, Bain AR, Madden D, Maslov PZ and Dujic Z.

592 Regulation of brain blood flow and oxygen delivery in elite breath-hold divers. *Journal of*

593 *Cerebral Blood Flow and Metabolism*. 2015;35:66-73.

594 21. Myerson A and Loman J. Internal jugular venous pressure in man: Its relationship to
595 cerebrospinal fluid and carotid arterial pressures. *Archives of Neurology and Psychiatry*.
596 1932;27:836–846.

597 22. Bailey DM, Willie CK, Hoiland RL, Bain AR, MacLeod DB, Santoro MA, DeMasi DK,

598 Andrijanic A, Mijacika T, Barak OF, Dujic Z and Ainslie PN. Surviving without oxygen: how low
599 can the human brain go? *High altitude medicine & biology*. 2017;18:73-79.

600 23. Fall L, Brugniaux JV, Davis D, Marley CJ, Davies B, New KJ, McEneny J, Young IS and601 Bailey DM. Redox-regulation of haemostasis in hypoxic exercising humans: a randomised

28

602 double-blind placebo-controlled antioxidant study. *The Journal of physiology*. 2018;596:4879-

603 4891.

- 604 24. Bain AR, Ainslie PN, Hoiland RL, Barak OF, Drvis I, Stembridge M, MacLeod DM,
- 605 McEneny J, Stacey BS, Tuaillon E, Marchi N, De Maudave AF, Dujic Z, MacLeod DB and Bailey
- 606 DM. Competitive apnea and its effect on the human brain: focus on the redox regulation of
- 607 blood-brain barrier permeability and neuronal-parenchymal integrity. FASEB journal : official
- 608 publication of the Federation of American Societies for Experimental Biology. 2018;32:2305-
- **609** 2314.
- **610** 25. Turrens JF. Mitochondrial formation of reactive oxygen species. *Journal of Physiology*.
- **611** 2003;552.2:335-344.
- 612 26. Murphy MP. How mitochondria produce reactive oxygen species. *The Biochemical*613 *journal*. 2009;417:1-13.
- 614 27. Augusto O and Truzzi DR. Carbon dioxide redox metabolites in oxidative eustress and
 615 oxidative distress. *Biophys Rev.* 2021;13:889-891.

616 28. Bailey DM, Taudorf S, Berg RMG, Lundby C, McEneny J, Young IS, Evans KA, James PE,

617 Shore A, Hullin DA, McCord JM, Pedersen BK and Moller K. Increased cerebral output of free

618 radicals during hypoxia: implications for acute mountain sickness? American Journal of

- 619 *Physiology (Regulatory, Integrative and Comparative Physiology)*. 2009;297:R1283-1292.
- 620 29. Bailey DM. Oxygen and brain death; back from the brink. *Experimental physiology*.621 2019;104:1769-1779.
- 622 30. Bailey DM, Young IS, McEneny J, Lawrenson L, Kim J, Barden J and Richardson RS.
- 623 Regulation of free radical outflow from an isolated muscle bed in exercising humans.
- 624 American Journal of Physiology (Heart and Circulatory Physiology). 2004;287:H1689-H1699.

29

625 31. Janigro D, Bailey DM, Lehmann S, Badaut J, O'Flynn R, Hirtz C and Marchi N.

- 626 Peripheral blood and salivary biomarkers of blood-brain barrier permeability and neuronal
- 627 damage: clinical and applied concepts. *Frontiers in Neurology*. 2021.
- 628 32. Jia L, Bonaventura C, Bonaventura J and Stamler JS. S-nitrosohaemoglobin: a dynamic
- activity of blood involved in vascular control. *Nature*. 1996;380:221-6.
- 630 33. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw
- 631 MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO and
- 632 Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human
- 633 circulation. *Nature Medicine*. 2003;9:1498-505.
- 634 34. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM. Activation of
- 635 nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature*.636 1999;399:601-5.
- 637 35. O'Gallagher K, Rosentreter RE, Elaine Soriano J, Roomi A, Saleem S, Lam T, Roy R,
 638 Gordon GR, Raj SR, Chowienczyk PJ, Shah AM and Phillips AA. The Effect of a Neuronal Nitric
 639 Oxide Synthase Inhibitor on Neurovascular Regulation in Humans. *Circ Res.* 2022;131:952640 961.
- Gladwin MT, Shelhamer JH, Schechter AN, Pease-Fye ME, Waclawiw MA, Panza JA,
 Ognibene FP and Cannon RO, III. Role of circulating nitrite and S-nitrosohemoglobin in the
 regulation of regional blood flow in humans. *Proceedings of the National Academy of Sciences*of the United States of America. 2000;97:11482-11487.
- 645 37. Stamler J, Jia L, Eu J, McMahon T, Demchenko I, Bonaventura J, Gernet K and
 646 Piantadosi C. Blood Flow Regulation by S-Nitrosohemoglobin in the Physiological Oxygen
 647 Gradient. *Science*. 1997;276:2034-2037.

30

648 38. Pawloski JR, Hess DT and Stamler JS. Export by red blood cells of nitric oxide649 bioactivity. *Nature*. 2001;409:622-6.

650 39. Ladurner A, Schmitt CA, Schachner D, Atanasov AG, Werner ER, Dirsch VM and Heiss

651 EH. Ascorbate stimulates endothelial nitric oxide synthase enzyme activity by rapid

652 modulation of its phosphorylation status. *Free radical biology & medicine*. 2012;52:2082-90.

40. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, Gow AJ,

654 Pawloski JR, Watke P, Singel DJ, Piantadosi CA and Stamler JS. Nitric oxide in the human

655 respiratory cycle. *Nature Medicine*. 2002;8:711-7.

41. Gladwin MT, Wang X, Reiter CD, Yang BK, Vivas EX, Bonaventura C and Schechter AN.

657 S-Nitrosohemoglobin is unstable in the reductive erythrocyte environment and lacks O2/NO-

658 linked allosteric function. *The Journal of biological chemistry*. 2002;277:27818-28.

Wang X, Bryan NS, MacArthur PH, Rodriguez J, Gladwin MT and Feelisch M.
Measurement of nitric oxide levels in the red cell: validation of tri-iodide-based
chemiluminescence with acid-sulfanilamide pretreatment. *The Journal of biological chemistry*. 2006;281:26994-7002.

43. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C,
Hogg N, Schechter AN and Gladwin MT. Enzymatic function of hemoglobin as a nitrite
reductase that produces NO under allosteric control. *Journal of Clinical Investigation*.
2005;115:2099-107.

667 44. Guzy R, Hoyos B, Robin E, Chen H, Liu L, Mansfield K, Simon M, Hammerling U and
668 Schumacker P. Mitochondrial complex III is required for hypoxia-induced ROS production and
669 cellular oxygen sensing. *Cell Metabolism*. 2005;1:401-8.

670 45. Williams NH and Yandell JK. Outer-sphere electron-transfer reactions of ascorbic671 anions. *Australian Journal of Chemistry*. 1982;35:1133-1144.

31

46. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, a-

tocopherol, and ascorbate. Archives of Biochemistry and Biophysics. 1993;300:535-543.

674

675 LEGENDS

676 Figure 1. Experimental hypotheses (A) and design (B)

677 A. Predicted differential disruption of cerebral redox homeostasis and implications for 678 cerebral bioenergetic function in response to pathological extremes of oxygen (O_2) and 679 carbon dioxide (CO₂) during hypoxemic hypercapnia (HHA, prior normoxic normoventilation) 680 and isolated hyperoxemic hypercapnia (IHA, prior hyperoxic hyperventilation) apneas. O_2/CO_2 681 sensing by the red blood cell (RBC) and mitochondrion is allosterically coupled to formation of nitric oxide (NO[•])⁴³ and reactive oxygen/nitrogen (ROS/RNS)⁴⁴ species that titrate (global) 682 683 cerebral blood flow (gCBF) coupling substrate (O_2 and glucose) delivery to demand. The more 684 marked reduction in arterial partial pressure of oxygen (PO_2) during the HHA trial is hypothesized to induce a more pronounced elevation in cerebral oxidative-nitrosative stress 685 686 (OXNOS) reflected by a free radical-mediated reduction in vascular NO bioavailability 687 (manifest as increased net cerebral output of free radicals and lipid peroxidants and 688 corresponding lower net cerebral uptake of nitrite (NO_{2}) or S-nitrosohemoglobin (SNO-Hb) 689 leading to a suppression of cerebral hypoxic vasodilation relative to IHA trial. Note typical 690 human experimental setup highlighting arterial-jugular venous (transcerebral) sampling of 691 blood combined with volumetric assessment of gCBF. R[•], free radical; NO₂, nitrite; N₂O₃, 692 nitrogen tri-oxide; ONOO, peroxynitrite (not measured); PaO₂, arterial partial pressure of 693 oxygen; PaCO₂, arterial partial pressure of carbon dioxide; a-jv_D, arterio-jugular venous concentration difference; SNA, sympathetic nervous activity (not measured). B. Two 694

32

695 submaximal (practice) apneas preceded separate trials involving prior normoxic (21 % O₂) 696 normoventilation resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the 697 second followed prior hyperoxic hyperventilation (100 % O₂), designed to prevent hypoxemia 698 resulting in isolated hypercaphic apnea (IHA). The first practice apnea was performed at 699 functional residual capacity (FRC) for 6 involuntary body movements (IBMs) and the second 700 practice at total lung capacity (TLC) for 10 IBMs. Both maximal apneas were performed at 701 TLC. Measurements were performed at baseline and timed to coincide with the end of each 702 maximal apnea.

703

704 Figure 2. Transcerebral exchange of oxidative stress biomarkers

705 Values are mean \pm SD; Separate trials involving prior normoxic (21 % O₂) normoventilation 706 resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the second followed prior 707 hyperoxic (100 % O₂) hyperventilation, designed to prevent hypoxemia resulting in isolated hypercapnic apnea (IHA); Circles and triangles denote individual data points for participants 708 709 during the NX and HX trials respectively; Total lipid soluble antioxidants (LSA) calculated as the 710 cumulative concentration of α/γ -tocopherol, α/β -carotene, retinol and lycopene; A^{-} , 711 ascorbate free radical; LOOH, lipid hydroperoxides. Exchange calculated as the product of 712 global cerebral plasma/serum flow and arterio-jugular venous concentration difference. 713 Positive or negative gradients reflect net cerebral uptake (loss or consumption) or output 714 (gain or formation) respectively. Since the concentration of ascorbate in human plasma is 715 orders of magnitude greater than any oxidizing free radical combined with the low oneelectron reduction potential for the $A^{-}/ascorbate$ monanion (AH⁻) couple ($E^{\circ'}$ = 282 mV)⁴⁵. 716 717 any oxidizing species (R[•]) generated locally within the cerebral circulation will result in the one-electron oxidation of ascorbate to form the distinctive EPR-detectable A^{•-} doublet (R[•] + 718

33

719 $AH^{-} \rightarrow A^{+} + R-H$, Panel D inset with main coupling hydrogen highlighted in red)⁴⁶. *different 720 between state for given trial (*P* < 0.05); †different between trial for given state (*P* < 0.05).

721

722

723

724 Figure 3. Local distribution of nitric oxide (NO) metabolites

725 Values are mean \pm SD; Separate trials involving prior normoxic (21 % O₂) normoventilation 726 resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the second followed prior 727 hyperoxic hyperventilation (100 % O₂), designed to prevent hypoxemia resulting in isolated hypercapnic apnea (IHA); NO, nitric oxide; NO₂, nitrite; RSNO, S-nitrosothiols; SNO-Hb, S-728 729 nitrosohemoglobin; HbNO, nitrosylhemoglobin; A, arterial; V, venous. Plasma NO_2 : Trial (P = 730 0.010); State (P = 0.003); Site (P = < 0.001); Trial × Site (P = 0.048); RBC NO₂: Trial (P = 0.048); 731 Site (P = 0.047); SNO-Hb: Trial (P = 0.014); State (P = 0.036); Site (P = 0.019); Trial × State (P = 732 0.022); HbNO: Trial (P = 0.002); Site (P = <0.001); Trial × State (P = 0.024); Trial × State × Site (P = 0.045); Total plasma NO: Trial (P = 0.009); State (P = 0.033); Site (P = <0.001); Trial × Site 733 734 (P = 0.042); Total RBC NO: State (P = 0.042); Total plasma + RBC NO: Trial (P = 0.044); Site (P = 735 0.036). *different between state for given trial (P < 0.05); †different between trial for given 736 state (P < 0.05).

737

738 Figure 4. Transcerebral exchange of nitrosative stress biomarkers

739 Values are mean \pm SD; Separate trials involving prior normoxic (21 % O₂) normoventilation 740 resulting in severe hypoxemic hypercapnia apnea (HHA) whereas the second followed prior 741 hyperoxic hyperventilation (100 % O₂), designed to prevent hypoxemia resulting in isolated

742	hypercapnic apnea (IHA); Circles and triangles denote individual data points for participants
743	during the NX and HX trials respectively; NO, nitric oxide; NO_2^{-} , nitrite; RSNO, S-nitrosothiols;
744	SNO-Hb, S-nitrosohemoglobin; HbNO, nitrosylhemoglobin. Exchange calculated as the
745	product of global cerebral plasma (A-C) or red blood cell (RBC, D-G) or whole blood (H) flow
746	and arterio-jugular venous concentration difference. Positive or negative gradients reflect net
747	cerebral uptake (loss or consumption) or output (gain or formation) respectively. Note typical
748	smoothed traces for arterial concentration of metabolites obtained by ozone-based
749	chemiluminescence (same scale). *different between state for given trial ($P < 0.05$); †different
750	between trial for given state ($P < 0.05$).

35

751 SUPPLEMENTAL MATERIAL

752 Supplemental Table 1. Blood gas variables

- 753 Values are mean \pm SD; PO₂/PCO₂, partial pressure of oxygen/carbon dioxide; SO₂,
- 754 oxyhemoglobin saturation; cO_2 , oxygen content; H^+ , hydrogen ions HCO_3^- , bicarbonate ions;
- **755** Hb, hemoglobin; Hct, hematocrit. *different between state for given trial and site (P < 0.05);
- **756** +different between trial for given state and site (P < 0.05).
- 757

758 Supplemental Table 2. Cardiopulmonary function

- 759 Values are mean ± SD; HR, heart rate; SV, stroke volume; Q, cardiac output; MAP, mean
- 760 arterial pressure; IJVP, internal jugular venous pressure; CPP, cerebral perfusion pressure. Δ,
- apnea minus eupnea; *different between state for given trial (*P* < 0.05); †different between
- 762 trial for given state or Δ (*P* < 0.05).
- 763

764 Supplemental Table 3. Cerebral bioenergetic function

Values are mean ± SD; \dot{Q}_{ICA} , internal carotid artery flow; \dot{Q}_{VA} , vertebral artery flow; gCBF, global cerebral blood flow; gCDO₂, global cerebral delivery of oxygen; gCD_{Glucose}, global cerebral delivery of glucose; CMR, cerebral metabolic rate; Δ, apnea minus eupnea. *different between state for given trial (*P* < 0.05); †different between trial for given state (*P* < 0.05).

770

771 Table 1. Oxidative stress

772 Values are mean ± SD; a-v_D, arterio-jugular venous concentration difference; Total lipid 773 soluble antioxidants (LSA) calculated as the cumulative concentration of α/γ -tocopherol, α/β -774 carotene, retinol and lycopene; A⁻⁻, ascorbate free radical; LOOH, lipid hydroperoxides.

36

775 Positive or negative a-v_D reflects cerebral uptake (loss or consumption) or output (gain or

formation) respectively.

777

778 Table 2. Nitrosative stress

- 779 Values are mean \pm SD; a-v_D, ; NO, nitric oxide; NO₂, nitrite; RSNO, S-nitrosothiols; SNO-Hb, S-
- 780 nitrosohemoglobin; HbNO, nitrosylhemoglobin. Positive or negative a-v_D reflects cerebral
- 781 uptake (loss or consumption) or output (gain or formation) respectively. *different between
- site for given trial and state (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05); †different between trial for given state and site (P < 0.05);

783 0.05).

37

784 ACKNOWLEDGMENTS

- 785 The authors acknowledge the cheerful cooperation of all participants. We are also indebted
- to Professor IS Young and Dr Jane McEneny for specialist technical input.
- 787

788 SOURCES OF FUNDING

This study was funded by a Royal Society Wolfson Research Fellowship (#WM170007) and Higher Education Funding Council for Wales (Dr Bailey), Canada Research Chair (CRC) and Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery grant (Dr Ainslie), NSERC (Drs Bain and Hoiland), Autonomic Province of Vojvodina, Serbia (#142-451-2541, Dr Barak) and Croatian Science Foundation Grant (#IP-2014-09-1937, Drs Barak, Drvis

- **794** and Ainslie).
- 795

796 DISCLOSURES

797 Dr Bailey is Editor-in-Chief of Experimental Physiology, Chair of the Life Sciences Working 798 Group, member of the Human Spaceflight and Exploration Science Advisory Committee to 799 the European Space Agency, member of the Space Exploration Advisory Committee to the UK 800 Space Agency, member of the National Cardiovascular Network for Wales and South East 801 Wales Vascular Network and is affiliated to the companies FloTBI, Inc. and Bexorg, Inc. 802 focused on the technological development of novel biomarkers of brain injury in humans.

Supplemental Table 1. Blood gas variables

Trial:	Hypoxemic Hypercapnia Apnea ($n = 10$)					Isolated Hyperca	pnic Apnea (<i>n</i> = 10)		
State:	Eupnea		Ар	Apnea		Eupnea		ea	
Site:	Arterial	Venous	Arterial	Venous	Arterial	Venous	Arterial	Venous	
PO ₂ (mmHg)	97 ± 12	34 ± 4	36 ± 5*	28 ± 5*	589 ± 23†	28 ± 10	425 ± 79*†	80 ± 9*†	
Trial (P = <0.001); State (P = <0.001); Site (P = <0.001); Trial × Site (P = <0.001); State × Site (P = <0.001); Trial × State × Site (P = <0.001)									
SO ₂ (%)	98 ± 1	58 ± 7	60 ± 11*	$40 \pm 11^{*}$	$100 \pm 0^+$	51 ± 19	$100 \pm 0^{*+}$	93 ± 2*†	
Trial (P = <0.001); Site (H	P = <0.001); Trial	× State (P = <0.00	1); State × Site (P =	= <0.001);	tate × Site (P = 0.0	08)			
cO ₂ (mL/dL)	18.3 ± 1.7	10.7 ± 1.6	11.7 ± 2.4*	8.0 ± 2.6*	20.6 ± 2.0†	9.7 ± 3.6	20.0 ± 1.6*†	17.8 ± 1.9*†	
Trial (P = <0.001); Site (H	P = <0.001); Trial	× State (P = <0.00	1); State × Site (P =	= <0.001);	tate × Site (P = 0.0	06)			
PCO ₂ (mmHg)	36 ± 5	47 ± 5	51 ± 3*	$54 \pm 4^{*}$	16 ± 4†	31±6†	58 ± 5*†	59 ± 15*	
Trial (P = 0.006); State (P = <0.001); Site ('P = <0.001); Trial	× State (P = <0.00.	1);	= <0.001); Trial × S	tate × Site (P = 0.0	33)		
pH (units)	7.440 ± 0.043	7.384 ± 0.032	7.360 ± 0.023*	7.348 ± 0.021*	7.700 ± 0.078†	7.542 ± 0.071†	7.283 ± 0.043*+	7.306 ± 0.154*	
Trial (P = 0.005); State (P = <0.001); Site ((P = 0.001); Trial ×	State (P = <0.001)); State × Site (P =	<0.001); Trial × Sta	ate × Site (P = 0.00	8)		
H^+ (μ M)	36 ± 3	41 ± 3	44 ± 2	45 ± 2	20 ± 4	29 ± 4	52 ± 5	52 ± 12	
Trial (P = 0.041); State (P = <0.001); Site ((P = 0.001);	State (P = <0.001)); State × Site (P =	<0.001); Trial × Sta	ate (P = <0.001)			
HCO_{2}^{-} (mM)	24.2 ± 2.5	27.9 ± 2.3	27.9 ± 3.1*	29.8 ± 2.0*	19.8 ± 2.0†	26.0 ± 2.2†	27.2 ± 1.9*	27.9 ± 2.1*†	
Trial (P = 0.001); State (Trial (P = 0.001); State (P = <0.001); Site (P = <0.001); Trial × State (P = 0.002); State × Site (P = <0.001); Trial × State × Site (P = <0.001)								
Hb (g/dL)	13.7 ± 1.4	13.7 ± 1.4	14.3 ± 1.2	14.5 ± 1.0	14.0 ± 1.4	14.2 ± 1.5	14.0 ± 1.2	14.1 ± 1.4	
<i>Trial × State (P = 0.034)</i>									
Hct (%)	42 ± 4	42 ± 4	44 ± 4	44 ± 3	43 ± 4	44 ± 5	43 ± 4	43 ± 4	
Trial × State (P = 0.023)									

Trial: I_{vin} Hyperconnic Hyperconnic Anneo (n = 10) Isolated Hyperconnic Anneo (n = 10)									
THAI:	нурохе	mic Hypercaphia	Aprilea ($n = 10$)	Isolate	ed Hypercaphic A	(n = 10)			
State:	Eupnea	Apnea	Δ	Eupnea	Apnea	Δ			
HR (b/min)	64 ± 7 59 ± 14		-5 ± 12	65 ± 11	69 ± 13	4 ± 18			
SV (mL/min)	78 ± 16	67 ± 16*	-11 ± 15	86 ± 17†	90 ± 17†	5 ± 12†			
Trial (P = 0.001)); Trial × State (I	P = 0.001)							
Q (L/min)	4.92 ± 0.91	3.91 ± 1.17*	-1.01 ± 1.21	5.46 ± 1.01	6.29 ± 1.97†	0.83 ± 1.73†			
Trial (P = 0.001)); Trial × State (I	P = 0.029)							
MAP (mmHg)	116 ± 8	177 ± 8*	61 ± 9	111 ± 8†	158 ± 16*†	$47 \pm 14^{*+}$			
Trial (P = 0.001));	001); Trial × State	e (P = 0.018)						
IJVP (mmHg)	10 ± 2	22 ± 1*	12 ± 2	10 ± 2	17 ± 5*†	7 ± 5*†			
Trial (P = 0.015));	001); Trial × State	e (P = 0.016)						
CPP (mmHg)	106 ± 9	155 ± 7	49 ± 8	101 ± 9	141 ± 16	40 ± 13			
Trial (P = 0.002)). State (P = <0 ()))). Trial x State	P(P = 0.112)						

Supplemental Table 2. Cardiopulmonary function

40

Supplemental Table 3. Cerebral bioenergetic function

Trial:	Нурс	oxemic Hypercapnia Ap	Apnea ($n = 10$) Isolated Hypercaphic Apnea ($n = 10$			
State:	Eupnea	Apnea	Δ	Eupnea	Apnea	Δ
Perfusion						
_ Q _{ICA} (mL/min)	458 ± 55	848 ± 148*	390 ± 119	317 ± 92†	938 ± 211*	621 ± 174†
State (P = <0.001); Trial × State	e (P = 0.001)					
Ċ _{va} (mL/min)	177 ± 82	307 ± 133*	130 ± 54	113 ± 55†	357 ± 198*	244 ± 146†
State (P = <0.001); Trial × State	e (P = 0.009)					
gCBF (mL/min)	635 ± 84	1155 ± 147*	520 ± 114	31 ± 7†	92 ± 22*	865 ± 260†
State (P = <0.001); Trial × State	e (P = 0.002)					
Metabolism						
gCDO ₂ (mL/min)	116 ± 22	137 ± 43*	20 ± 30	88 ± 20†	259 ± 63*†	171 ± 52†
Trial (P = <0.001); State (P = <0	0.001); Trial × State	(P = <0.001)				
gCD _{Gluc} (mM/min)	3.45 ± 0.60	6.30 ±1.07*	2.85 ± 0.77	2.20 ± 0.49†	7.48 ± 1.57*†	5.28 ± 1.40+
State (P = <0.001); Trial × State	e (P = <0.001)					
gCMRO ₂ (mL/min)	47 ± 8	43 ± 12	-5 ± 17	48 ± 19	28 ± 8	-19 ± 18
State (P = 0.015)						
gCMR _{Glucose} (mM/min)	0.37 ± 0.09	0.30 ± 0.09	-0.07 ± 0.14	0.47 ± 0.14	0.50 ± 0.52	0.04 ± 0.58
Trial (P = 0.044)						

Table 1. Oxidative stress

Trial:	Ну	poxemic Hyperca	ipnia Apnea (<i>n</i> = 1	10)	Isolated Hypercapnic Apnea (n = 10)				
State:	Eupnea		Ар	Apnea		Eupnea		nea	
Site:	Arterial	Venous	Arterial	Venous	Arterial	Venous	Arterial	Venous	
Antioxidants		_		_		_		_	
Ascorbate (µM)	59.3 ± 11.0	59.2 ± 10.0	61.8 ± 8.9	53.5 ± 6.4	61.0 ± 6.7	60.5 ± 5.3	63.0 ± 5.6	60.0 ± 3.7	
Site (P = 0.007); Trial × Si	ite (P = 0.017); Stat	e × Site (P = 0.01	5)						
a-v _D (μM)	0.2 :	± 4.3	8.3 :	± 5.6	0.5 :	± 4.9	3.0 :	± 4.0	
Trial (P = 0.017); State (P	P = 0.015)								
α-tocopherol (μM)	22.1 ± 3.9	21.7 ± 3.2	24.4 ± 3.0	20.4 ± 3.4	22.5 ± 4.9	22.7 ± 4.1	22.7 ± 2.9	21.3 ± 3.2	
Site (P = 0.008); State × 5	Site (P = 0.011)								
a-v _D (μM)	0.3 ± 1.5		4.0 ± 2.6		-0.1	± 4.2	1.4 ± 2.6		
State (P = 0.010)									
Total LSA (μM)	25.6 ± 3.6	25.2 ± 3.1	28.0 ± 2.6	23.7 ± 3.0	26.0 ± 4.7	26.2 ± 3.9	26.0 ± 2.5	24.4 ± 2.7	
Site (P = 0.006); State × 5	Site (P = 0.010)								
a-v _D (μM)	0.4 :	± 2.1	4.3	± 2.4	-0.1	± 4.7	1.6	± 2.6	
State (P = 0.011)									
Free radicals									
A^{-} (AU × 10 ²)	320 ± 107	313 ± 98	344 ± 95	473 ± 127	322 ± 70	333 ± 102	363 ± 143	386 ± 129	
State (P = 0.009); Site (P	= 0.046); State × Si	te (P = 0.048)							
$a-v_D (AU \times 10^2)$	6 ±	130	-129	-129 ± 96		-12 ± 143		-24 ± 91	
State (P = 0.048)									
Lipid peroxidation									
LOOH (µM)	1.15 ± 0.17	1.16 ± 0.13	1.22 ± 0.25	1.74 ± 1.20	1.19 ± 0.15	1.25 ± 0.22	1.27 ± 0.18	1.45 ± 0.24	
State (P = 0.038); Site (P	= 0.045); State × Si	te (P = 0.048)							
a-v _D (μM)	-0.01	± 0.14	-0.52 ± 0.97		-0.07 ± 0.23		-0.18 ± 0.15		
State (P = 0.047)									

Table 2. Nitrosative stress

Trial:	Hypoxemic Hypercapnia Apnea ($n = 10$)				Isolated Hypercapnic Apnea ($n = 10$)			
State:	Eupnea		Apnea		Eupnea		Apn	ea
Site:	Arterial	Venous	Arterial	Venous	Arterial	Venous	Arterial	Venous
Plasma								
NO_{2}^{-} (nM)	161 ± 45	149 ± 35	124 ± 45	85 ± 34	210 ± 80	154 ± 42	176 ± 55	108 ± 45
Trial (P = 0.010); State (P = 0.003); Site (P = <0.001); Trial × Site (P = 0.048)								
a-v _D (nM)	12 ±	: 48	39 ±	46	55 ±	55	68 ± 34	
Trial (P = 0.048)								
RSNO (nM)	9 ± 9	7 ± 8	8 ± 11	6 ± 9	6 ± 5	4 ± 4	5 ± 6	5 ± 2
a-v _D (nM)	2 ±	: 6	2 ±	4	1 ±	± 3	1 ±	4
Total NO (nM)	170 ± 43	155 ± 37	132 ± 52	91 ± 39	215 ± 82	159 ± 45	181 ± 58	113 ± 47
Trial (P = 0.009); State (P =	0.033); Site (P =	<0.001); Trial × .	Site (P = 0.042)					
a-v _D (nM)	14 ±	: 46	41 ±	46	57 1	± 55	68 ±	37
Trial (P = 0.042)								
Red blood cell								
NO_{2}^{-} (nM)	171 ± 62	138 ± 39	190 ± 71	158 ± 52	216 ± 84	174 ± 65	202 ± 72	210 ± 96
Trial (P = 0.048); Site (P = 0.	.047)							
a-v _D (nM)	33 ±	64	33 ± 94		42 ± 106		-8 ± 128	
SNO-Hb (nM)	10 ± 3	15 ± 5	16 ± 5	32 ± 30	9 ± 4	14 ± 6	9 ± 3	12 ± 3
Trial (P = 0.014); State (P =	0.036); Site (P =	0.019); Trial × Si	tate (P = 0.022)					
a-v _D (nM)	-5 -	£ 5	-16 ± 31		-5 ± 6		-3 ± 5	
HbNO (nM)	21 ± 5	41 ± 15*	32 ± 20	66 ± 38*	7 ± 3†	30 ± 16*	11 ± 8†	24 ± 17†
Trial (P = 0.002); Site (P = <	0.001); Trial × Si	tate (P = 0.024);	Trial × State × Site	r (P = 0.045)				
a-v _D (nM)	-20 ±	± 16	-34 ±	: 31	-1 ± 13		-29 ±	33†
Trial × State (P = 0.049)								
Total NO (nM)	202 ± 62	194 ± 47	239 ± 81	256 ± 81	232 ± 81	218 ± 65	222 ± 72	245 ± 103
State (P = 0.042)								
a-v _D (nM)	8 ± 68		-17 ± 120		14 ± 112		-24 ± 139	
Plasma + Red blood cell								
Total NO (nM)	371 ± 69	349 ± 50	371 ± 103	347 ± 107	447 ± 96	376 ± 93	403 ± 88	358 ± 134
Trial (P = 0.044); Site (P = 0.	.036)							
a-v _D (nM)	22 ± 68		24 ± 140		71 ± 85		44 ± 161	



Figure 1. Experimental hypotheses (A) and design (B)





Figure 3. Local distribution of nitric oxide (NO) metabolites



Figure 4. Transcerebral exchange of nitrosative stress biomarkers